{"id":109211,"date":"2020-05-06T12:38:12","date_gmt":"2020-05-06T16:38:12","guid":{"rendered":"https:\/\/www.ucf.edu\/news\/?p=109211"},"modified":"2020-05-06T12:38:12","modified_gmt":"2020-05-06T16:38:12","slug":"ucf-developed-cancer-fighting-nanoparticle-heads-to-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.ucf.edu\/news\/ucf-developed-cancer-fighting-nanoparticle-heads-to-clinical-trials\/","title":{"rendered":"Âé¶¹Ó³»´«Ã½-Developed Cancer-Fighting Nanoparticle Heads to Clinical Trials"},"content":{"rendered":"
A cell-based cancer immunotherapy that utilizes a nanoparticle developed at Âé¶¹Ó³»´«Ã½ to stimulate a patient\u2019s natural cancer-killing cells has just received the green light to proceed directly into a Phase II clinical trial.<\/p>\n
College of Medicine Associate Professor Alicja Copik and her team developed the technique in 2016 and then co-founded the company CytoSen to take the concept to market. In 2019, the company was acquired by Netherlands-based bio-pharmaceutical firm Kiadis Pharma<\/a>, which saw the potential to develop new treatment options for cancer patients.<\/p>\n Today, Kiadis Pharma, announced it received approval from the U.S. Food and Drug Administration to start its NK-REALM Phase II clinical trial. It had submitted the request to develop K-NK002, as an adjunctive therapy to use with people receiving hematopoietic stem cell transplantation to fight blood cancers. The goal would be to add it to the standard care delivered to these patients to reduce the rate in which the cancers come back.<\/p>\n \u201cIt takes years to make a discovery that doesn\u2019t get a lot of attention at the time, but later it can make a huge difference,\u201d Copik says. \u201cI\u2019m so happy to see this moving forward with hopes it will soon make a positive impact on cancer patients. That\u2019s what it is all about, giving patients a fighting chance of cancer survival.\u201d<\/p>\n